Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential determination of ED50 of nalbuphine for intraoperative analgesia in elderly percutaneous kyphoplasty
ChiCTR2300071476Phase 4Not yet recruiting
- Sponsor
- 964th Hospital of the Joint Support Force of the People's Liberation Army
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nalbuphine in postoperative pain and Intraoperative pain, sponsored by 964th Hospital of the Joint Support Force of the People's Liberation Army. Primary endpoints: Median effective dose (ED50) of nalbuphine, Dosage of nalbuphine and 1 more. Planned start May 2023; status: not yet recruiting.
02
Drugs
nalbuphine
03
Conditions
postoperative painIntraoperative pain
Beyond the preview
Go deeper on ChiCTR2300071476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071476.